Literature DB >> 21282484

Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management with normative values from the National Health and Nutrition Examination Survey.

Charles D Burger1, Aimee J Foreman, Dave P Miller, Robert E Safford, Michael D McGoon, David B Badesch.   

Abstract

OBJECTIVE: To investigate the correlation between body mass index (BMI) and pulmonary artery systolic pressure in a large population of patients with pulmonary arterial hypertension (PAH). PATIENTS AND METHODS: The BMI of patients with group 1 PAH enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) was compared with that of age- and sex-matched controls in the National Health and Nutrition Examination Survey (NHANES) to clarify whether obesity is linked with PAH. The diagnosis of PAH was defined in REVEAL by right-sided heart catheterization. Differences in BMI and the percentage of patients considered obese (BMI ≥30) and underweight (BMI <18.5) in various subgroups of patients enrolled in REVEAL from March 30, 2006, through September 11, 2007, were determined.
RESULTS: Mean BMI was no different for patients with PAH (n=2141) than for the NHANES normal comparison group; however, the proportion of obese and underweight patients was increased in patients with PAH. Subgroup analysis demonstrated that subgroups with idiopathic PAH and those with PAH associated with drugs and toxins had both higher BMI and percentage of obese patients, whereas 3 other subgroups (those with PAH associated with congenital heart disease, connective tissue disease, and human immunodeficiency virus) had lower mean BMI.
CONCLUSION: Mean BMI of the REVEAL patients was the same as that of the NHANES normal comparison group; however, there were higher percentages of obese and underweight patients in REVEAL. This discrepancy can be explained by the balancing effect of more overweight and underweight patients in different PAH subgroups. The reason for the increased frequency of obesity in idiopathic PAH is unknown, and additional study is needed.

Entities:  

Mesh:

Year:  2011        PMID: 21282484      PMCID: PMC3031434          DOI: 10.4065/mcp.2010.0394

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  22 in total

1.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.

Authors:  L Abenhaim; Y Moride; F Brenot; S Rich; J Benichou; X Kurz; T Higenbottam; C Oakley; E Wouters; M Aubier; G Simonneau; B Bégaud
Journal:  N Engl J Med       Date:  1996-08-29       Impact factor: 91.245

2.  Severe pulmonary hypertension in postmenopausal obese women.

Authors:  Agne Taraseviciute; Norbert F Voelkel
Journal:  Eur J Med Res       Date:  2006-05-05       Impact factor: 2.175

3.  Prevalence of cardiovascular risk factors in adults with congenital heart disease.

Authors:  Philip Moons; Kristien Van Deyk; Davy Dedroog; Els Troost; Werner Budts
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2006-08

Review 4.  Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences.

Authors:  R Kessler; A Chaouat; E Weitzenblum; M Oswald; M Ehrhart; M Apprill; J Krieger
Journal:  Eur Respir J       Date:  1996-04       Impact factor: 16.671

5.  Obesity: preventing and managing the global epidemic. Report of a WHO consultation.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  2000

Review 6.  Anorectic drugs and pulmonary hypertension from the bedside to the bench.

Authors:  E D Michelakis; E K Weir
Journal:  Am J Med Sci       Date:  2001-04       Impact factor: 2.378

7.  Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects.

Authors:  B M McQuillan; M H Picard; M Leavitt; A E Weyman
Journal:  Circulation       Date:  2001-12-04       Impact factor: 29.690

8.  ESPEN Guidelines on Enteral Nutrition: Wasting in HIV and other chronic infectious diseases.

Authors:  J Ockenga; R Grimble; C Jonkers-Schuitema; D Macallan; J-C Melchior; H P Sauerwein; A Schwenk; U Süttmann
Journal:  Clin Nutr       Date:  2006-05-15       Impact factor: 7.324

9.  The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries.

Authors:  Adaani E Frost; David B Badesch; Robyn J Barst; Raymond L Benza; C Gregory Elliott; Harrison W Farber; Abby Krichman; Theodore G Liou; Gary E Raskob; Prieya Wason; Kathleen Feldkircher; Michelle Turner; Michael D McGoon
Journal:  Chest       Date:  2010-06-17       Impact factor: 9.410

10.  Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension.

Authors:  S Rich; L Rubin; A M Walker; S Schneeweiss; L Abenhaim
Journal:  Chest       Date:  2000-03       Impact factor: 9.410

View more
  18 in total

Review 1.  Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health.

Authors:  Carl D Koch; Mark T Gladwin; Bruce A Freeman; Jon O Lundberg; Eddie Weitzberg; Alison Morris
Journal:  Free Radic Biol Med       Date:  2016-12-16       Impact factor: 7.376

Review 2.  Pulmonary hypertension in obstructive sleep apnea: is it clinically significant? A critical analysis of the association and pathophysiology.

Authors:  Cyrus Kholdani; Wassim H Fares; Vahid Mohsenin
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

3.  Abnormal Glucose Metabolism and High-Energy Expenditure in Idiopathic Pulmonary Arterial Hypertension.

Authors:  Gustavo A Heresi; Steven K Malin; Jarrod W Barnes; Liping Tian; John P Kirwan; Raed A Dweik
Journal:  Ann Am Thorac Soc       Date:  2017-02

4.  Sympathetic cardiac hyperinnervation and atrial autonomic imbalance in diet-induced obesity promote cardiac arrhythmias.

Authors:  Belinda H McCully; Wohaib Hasan; Cole T Streiff; Jennifer C Houle; William R Woodward; George D Giraud; Virginia L Brooks; Beth A Habecker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-09-06       Impact factor: 4.733

5.  Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high-fat diet-induced obesity.

Authors:  Eric E Kelley; Jeff Baust; Gustavo Bonacci; Franca Golin-Bisello; Jason E Devlin; Claudette M St Croix; Simon C Watkins; Sonia Gor; Nadiezhda Cantu-Medellin; Eric R Weidert; Jefferson C Frisbee; Mark T Gladwin; Hunter C Champion; Bruce A Freeman; Nicholas K H Khoo
Journal:  Cardiovasc Res       Date:  2014-01-02       Impact factor: 10.787

Review 6.  Fatty acid metabolism in pulmonary arterial hypertension: role in right ventricular dysfunction and hypertrophy.

Authors:  Megha Talati; Anna Hemnes
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

7.  Obesity paradox in group 1 pulmonary hypertension: analysis of the NIH-Pulmonary Hypertension registry.

Authors:  S Mazimba; E Holland; V Nagarajan; A D Mihalek; J L W Kennedy; K C Bilchick
Journal:  Int J Obes (Lond)       Date:  2017-02-17       Impact factor: 5.095

8.  Use of pulmonary arterial hypertension-specific therapy in overweight or obese patients with obstructive sleep apnea and pulmonary hypertension.

Authors:  Adil Shujaat; Jason Bellardini; Ankur Girdhar; Abubakr A Bajwa
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

9.  Obesity and airway responsiveness: role of TNFR2.

Authors:  Alison S Williams; Lucas Chen; David I Kasahara; Huiqing Si; Allison P Wurmbrand; Stephanie A Shore
Journal:  Pulm Pharmacol Ther       Date:  2012-05-11       Impact factor: 3.410

10.  Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry.

Authors:  Hilary M DuBrock; Charles D Burger; Sonja D Bartolome; Jeremy P Feldman; D Dunbar Ivy; Erika B Rosenzweig; Jeffrey S Sager; Kenneth W Presberg; Stephen C Mathai; Matthew R Lammi; James R Klinger; Michael Eggert; Teresa De Marco; Jean M Elwing; David Badesch; Todd M Bull; Linda M Cadaret; Gautam Ramani; Thenappan Thenappan; H James Ford; Nadine Al-Naamani; Marc A Simon; Sula Mazimba; James R Runo; Murali Chakinala; Evelyn M Horn; John J Ryan; Robert P Frantz; Michael J Krowka
Journal:  Pulm Circ       Date:  2021-05-17       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.